A population-based meta-analysis of circulating GFAP for cognition and dementia risk.

Mitzi M GonzalesCrystal WiednerChen-Pin WangQianqian LiuJoshua C BisZhiguang LiJayandra J HimaliSaptaparni GhoshEmy A ThomasDanielle M ParentTiffany F KautzMatthew P PaseHugo J AparicioLuc DjousséKenneth J MukamalBruce M PsatyWilliam T LongstrethThomas H MosleyVilmundur GudnasonDjass MbangdadjiOscar L LopezKristine YaffeStephen SidneyR Nick BryanIlya M NasrallahCharles S DeCarliAlexa S BeiserLenore J LaunerMyriam FornageRussell P TracySudha SeshadriClaudia L Satizabal

Published in: Annals of clinical and translational neurology (2022)

Results support the potential role of circulating GFAP levels for aiding dementia risk prediction and improving clinical trial stratification in community settings.

Keyphrases

mild cognitive impairment
clinical trial
systematic review
cognitive impairment
healthcare
mental health
phase ii
open label
white matter
human health
case control
phase iii
risk assessment